Inflammatory, Lipid, Thrombotic, and Genetic Markers of Coronary Heart Disease Risk in the Women's Health Initiative Trials of Hormone Therapy

Rossouw, Jacques E.; Cushman, Mary; Greenland, Philip; Lloyd‐Jones, Donald M.; Bray, Paul F.; Kooperberg, Charles; Pettinger, Mary; Robinson, Jennifer G.; Hendrix, Susan L.; Hsia, Judith

doi:10.1001/archinte.168.20.2245

Cited by 76 publications

(92 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most case reports on estrogen-induced pancreatitis have reported concurrent hypertriglyceridemia. [7][8][9][10][11][12]14 Use of hormone replacement therapy may elevate triglycerides, 30 which, even at moderately elevated levels, have been associated with increased risk of acute pancreatitis. 31 The role of triglycerides in the pathogenesis of acute pancreatitis is not fully understood, but a key event is thought to be accumu lation of free fatty acids in the pancreas after hydrolysis of triglycerides by pancreatic lipase.…”

Section: Discussionmentioning

confidence: 99%

Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study

Oskarsson

Orsini

Sadr–Azodi

et al. 2014

CMAJ

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study

Oskarsson

Orsini

Sadr–Azodi

et al. 2014

CMAJ

View full text Add to dashboard Cite

show abstract

“…The studies included all adjudicated cases of CHD (n ϭ 359) (16,(41)(42)(43)(44) or ischemic stroke (n ϭ 205) (19,45 ) that occurred within the first 4 years of follow-up of the estrogen-progestin and estrogenalone trials. (A similar study of VTE is in progress.)…”

Section: Serum/plasma Biomarkersmentioning

confidence: 99%

“…These included higher concentrations of the inflammatory markers interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), and leukocyte count; the thrombotic markers D-dimer, factor VIII, and von Willebrand factor; homocysteine; and fasting insulin (16 ). Although most of these biomarkers did not significantly aid in identifying women more or less likely to experience a CHD event while taking HT, there was a significant interaction for factor VIII (P ϭ 0.04) and a suggestive interaction for homocysteine (P ϭ 0.12) (16 ).…”

Section: Reviewsmentioning

confidence: 99%

Menopausal Hormone Therapy and Cardiovascular Disease Risk: Utility of Biomarkers and Clinical Factors for Risk Stratification

Bassuk

Manson

2014

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND:Menopausal hormone therapy (HT) continues to have a clinical role in symptom management, but identifying women for whom benefits will outweigh the risks remains a challenge. Although hormone therapy (HT) is the most effective strategy for ameliorating vasomotor and other symptoms, randomized clinical trials show an unfavorable balance of benefits and risks for many women. However, closer examination of data from these trials suggests that it may be possible to classify women as better or worse candidates for HT by using individual risk stratification.CONTENT: Data from 2 landmark trials-the Women's Health Initiative (WHI) and the Heart and Estrogen/ progestin Replacement Study (HERS)-suggest an important role for clinical characteristics, serum biomarkers, genomic markers, and gene-environment interactions in developing a personalized approach to the prediction of risk for cardiovascular disease (CVD) events for women while on HT. The available data suggest several characteristics of women who are optimal candidates for HT use: younger age (Ͻ60 years), recent onset of menopause (Ͻ10 years), favorable lipid profile (LDL cholesterol Ͻ130 mg/dL or LDL/HDL cholesterol ratio Ͻ2.5), absence of metabolic syndrome, and absence of factor V Leiden genotype. The identification of other characteristics is an area of active investigation. In addition, women at high risk for venous thromboembolism should avoid systemic HT or choose a transdermal rather than oral delivery route.

show abstract

“…Dane dotyczące VTE były następujące: EPT powoduje 18 nowych przypadków VTE/10 000 kobiet/rok, zaś ET 7 nowych przypadków VTE/10 000 kobiet/rok (stosowanie samych estrogenów jest więc bezpieczniejsze od EPT). Obliczono również, że dla grupy kobiet w wieku 50-59 lat ryzyko VTE związa-ne z MHT jest wg kryteriów WHO Council for International Organizations of Medical Sciences niskie, gdyż w tej grupie wiekowej EPT powoduje 7 nowych przypadków VTE/10 000 kobiet/rok, a ET (tylko) 4 nowe przypadki VTE/10 000 kobiet/rok [16].…”

Section: Ryzyko żYlnej Choroby Zakrzepowo--zatorowej W Najnowszych Baunclassified

MHT vs. veins: is there any reason to fear?

Stachowiak¹

2013

View full text Add to dashboard Cite

StreszczenieŻylna choroba zakrzepowo-zatorowa (venous thromboembolism -VTE) jest zarówno przeciwwskazaniem, jak i powikłaniem terapii hormonalnej okresu menopauzy (menopausal hormone therapy -MHT). W pracy przedstawiono przegląd dostępnego piśmiennictwa na temat epidemiologii VTE, czynników ryzyka tej choroby, poświęcając najwięcej uwagi wpływowi MHT, począwszy od pierwszych doniesień z lat 70. XX w., a skończywszy na stanowisku North American Menopause Society (NAMS) z roku 2012. Ryzyko VTE będzie minimalne przy właściwej kwalifikacji pacjentek do MHT (m.in. eliminacja czynników ryzyka, stosowanie MHT w grupie kobiet poniżej 60. roku życia), wyborze przezskórnej drogi podania, redukcji dawek hormonów, zastosowaniu odpowiedniego progestagenu.Słowa kluczowe: menopauza, terapia hormonalna, żyły, droga przezskórna, progestageny. SummaryVenous thromboembolism (VTE) is both a contraindication and a complication of menopausal hormone therapies (MHT). This article presents a review of up-to-date literature on VTE epidemiology and its risk factors, paying attention mostly to the impact of MHT on VTE risk, starting from the 1970s reports to the North American Menopause Society position statement of 2012. The risk of VTE is minimized by the proper patients' qualification (e.g. elimination of risk factors, 50-59-aged patients), choice of transdermal MHT, hormone dose reduction and proper progestogen choice.

show abstract

Inflammatory, Lipid, Thrombotic, and Genetic Markers of Coronary Heart Disease Risk in the Women's Health Initiative Trials of Hormone Therapy

Cited by 76 publications

References 18 publications

Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study

Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study

Menopausal Hormone Therapy and Cardiovascular Disease Risk: Utility of Biomarkers and Clinical Factors for Risk Stratification

MHT vs. veins: is there any reason to fear?

Contact Info

Product

Resources

About